Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. RHOPRESSA OPHTHALMIC SOLUTION, 0.02% W/V [SIN16816P]

RHOPRESSA OPHTHALMIC SOLUTION, 0.02% W/V [SIN16816P]

Active ingredients: RHOPRESSA OPHTHALMIC SOLUTION, 0.02% W/V

Last updated 26 October 2025

Product Info

RHOPRESSA OPHTHALMIC SOLUTION, 0.02% W/V

[SIN16816P]

Product information

Active Ingredient and Strength

NETARSUDIL MESYLATE EQV NETARSUDIL - 0.02% W/V

Dosage Form

SOLUTION, STERILE

Manufacturer and Country

AERIE PHARMACEUTICALS IRELAND LIMITED - IRELAND

Registration Number

SIN16816P

Licence Holder

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01EX05

1. INDICATIONS AND USAGE
RHOPRESSA (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension [see section 12 Clinical Studies – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].

2. DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.

If one dose is missed, treatment should continue with the next dose in the evening. Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.

Due to netarsudil’s vasodilating properties, other eye drops should be administered before netarsudil. Eye ointments should be administered last.

4. CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients.